Scarica l'app Stockscreener
2.05
1.91%
-0.04
Pre-mercato:
2.38
0.33
+16.10%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ALZN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.09
Aprire:
$2.09
Volume 24 ore:
70,303
Relative Volume:
0.57
Capitalizzazione di mercato:
$6.44M
Reddito:
-
Utile/perdita netta:
$-6.24M
Rapporto P/E:
-0.367
EPS:
-5.5853
Flusso di cassa netto:
$-8.09M
1 W Prestazione:
-4.21%
1M Prestazione:
-18.97%
6M Prestazione:
-41.43%
1 anno Prestazione:
-81.78%
Intervallo 1D:
$2.04
$2.105
Intervallo di 1 settimana:
$2.04
$2.35
Portata 52W:
$1.88
$12.06
Alzamend Neuro Inc Stock (ALZN) Company Profile
Nome
Alzamend Neuro Inc
Settore
Industria
Telefono
844-722-6333
Indirizzo
3500 LENOX RD. NE, ATLANTA
Confronta ALZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
2.05 | 7.95M | 0 | -6.24M | -8.09M | -5.5853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.15 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.00 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.93 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.36 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.60 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-01 | Iniziato | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Borsa (ALZN) Ultime notizie
Why Alzamend Neuro Inc. stock remains undervaluedPortfolio Profit Report & AI Enhanced Trading Alerts - Newser
Is Alzamend Neuro Inc. stock attractive for passive investors2025 Earnings Impact & Daily Profit Focused Stock Screening - BỘ NỘI VỤ
Alzamend Neuro: Will Topline Data Spark Investor Interest? - RTTNews
Alzamend Neuro's AL001 formulation highlights its potential to treat disorders such a Alzheimer's - SelectScience
What margin trends mean for Alzamend Neuro Inc. stockWeekly Market Outlook & Verified Swing Trading Watchlists - newser.com
Why Alzamend Neuro Inc. stock could see breakout soonProduct Launch & High Return Trade Opportunity Guides - newser.com
Why Alzamend Neuro Inc. stock could benefit from AI revolutionTrade Risk Report & Daily Profit Maximizing Tips - newser.com
Alzamend Neuro Mourns Loss of Director Andrew Woo - The Globe and Mail
Can Alzamend Neuro Inc. stock sustain revenue growthMarket Risk Analysis & Pattern Based Trade Signal System - newser.com
Will Alzamend Neuro Inc. stock rally after Fed decisionsJuly 2025 Closing Moves & Safe Swing Trade Setup Alerts - newser.com
Will Alzamend Neuro Inc. stock reach all time highs in 2025Exit Point & Daily Technical Forecast Reports - newser.com
Alzamend completes clinical portion of phase II trial for lithium therapy - Investing.com Nigeria
Published on: 2025-11-19 13:20:00 - newser.com
Alzamend Neuro announces passing of board member Andrew H. Woo By Investing.com - Investing.com Australia
Comparing Alzamend Neuro Inc. in custom built stock radarsWeekly Risk Summary & Weekly Momentum Picks - newser.com
Alzamend Neuro announces completion of clinical portion of phase II clinical trial of AL001 "lithium in brain" study conducted at Massachusetts General Hospital - MarketScreener
Alzamend rises after completing mid-stage brain lithium study - TradingView
Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data - Stock Titan
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants - Benzinga
Multi asset correlation models including Alzamend Neuro Inc.Oil Prices & Fast Exit/Entry Strategy Plans - newser.com
Is Alzamend Neuro Inc. stock cheap compared to fundamentalsWeekly Trend Summary & Safe Capital Growth Plans - newser.com
Alzamend Neuro announces passing of board member Andrew H. Woo - Investing.com
Alzamend Neuro Announces Passing of Board Member Andrew H. Woo - TradingView
[8-K] Alzamend Neuro, Inc. Reports Material Event | ALZN SEC FilingForm 8-K - Stock Titan
Is Alzamend Neuro Inc a good long term investmentSector ETF Performance & Add These Before Everyone Else Does - earlytimes.in
How Alzamend Neuro Inc. stock reacts to job market dataJobs Report & AI Driven Stock Movement Reports - newser.com
Alzamend Neuro Inc Azioni (ALZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alzamend Neuro Inc Azioni (ALZN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
Oct 08 '25 |
Sale |
2.44 |
101,394 |
247,158 |
28,657 |
| AULT MILTON C III | Director |
Oct 09 '25 |
Sale |
2.32 |
20,397 |
47,390 |
8,260 |
| AULT MILTON C III | Director |
Oct 06 '25 |
Sale |
2.45 |
82,033 |
201,268 |
26,227 |
| AULT MILTON C III | Director |
Oct 07 '25 |
Sale |
2.49 |
57,379 |
142,954 |
68,848 |
| AULT MILTON C III | Director |
Oct 03 '25 |
Sale |
2.44 |
65,903 |
160,889 |
8,260 |
| AULT MILTON C III | Director |
Oct 01 '25 |
Sale |
2.35 |
36,777 |
86,378 |
94,849 |
| AULT MILTON C III | Director |
Oct 02 '25 |
Sale |
2.39 |
20,686 |
49,522 |
74,163 |
| AULT MILTON C III | Director |
Sep 29 '25 |
Sale |
2.31 |
38,324 |
88,490 |
35,192 |
| AULT MILTON C III | Director |
Sep 26 '25 |
Sale |
2.31 |
37,738 |
87,345 |
73,516 |
| AULT MILTON C III | Director |
Sep 30 '25 |
Sale |
2.33 |
3,566 |
8,321 |
31,626 |
0.93%
1.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):